Vaginal Dryness clinical trials

Explore recruiting vaginal dryness clinical trials.

Recruiting vaginal dryness studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Vaginal Dryness trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Hungary, Germany, Austria, Spain, Netherlands, Romania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of EXercise on quality of life of early breast cancer patients on treatment with adjuvant Aromatase Inhibitors with or without CDK4/6 inhibitors. "The EX-AI study"

Spain

Therapeutic use (Phase IV) EU CTIS Study details

The efficacy of the use of Cellular Matrix-BCT-HA (combination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid) compared to local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel) in women with genitourinary syndrome of menopause. A randomized controlled trial, with a second blind observer.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

ANISE-II; ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-concept trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Is there an effect of local vaginal estrogen treatment on the hemostatic parameters in postmenopausal women?

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensitive PIK3CA -Mutated, Hormone Receptor-Positive, HER2- Negative Advanced Breast Cancer

Germany, Italy, France, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Vaginal Dryness trials by city

Vaginal Dryness in Toronto Vaginal Dryness in Vancouver Vaginal Dryness in Montreal Vaginal Dryness in Calgary Vaginal Dryness in Edmonton Vaginal Dryness in Ottawa Vaginal Dryness in Winnipeg Vaginal Dryness in Quebec City Vaginal Dryness in Hamilton Vaginal Dryness in Kitchener Vaginal Dryness in London Vaginal Dryness in Halifax Vaginal Dryness in New York Vaginal Dryness in Los Angeles Vaginal Dryness in Chicago Vaginal Dryness in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease